{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T10:05:38Z","timestamp":1744625138513,"version":"3.37.3"},"reference-count":72,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2018,11,27]],"date-time":"2018-11-27T00:00:00Z","timestamp":1543276800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Hematological Oncology"],"published-print":{"date-parts":[[2019,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Recent advances in diffuse large B\u2010cell lymphomas have included both identification of high\u2010risk subtypes characterized by multiply relapsed and\/or refractory disease as well as novel treatment in the form of cellular therapy. Chimeric antigen receptor (CAR)\u2010T cell therapy is a recently developed approach to address the poor outcomes in this patient population. The CAR\u2010T cell construct has evolved although several iterations as it transitioned from the lab to the clinic. Three major studies have evaluated the efficacy of CD19\u2010directed CAR\u2010T cell therapy in aggressive B\u2010cell non\u2010Hodgkin lymphoma; each demonstrating durable complete remissions in heavily pretreated patients. The cost of this remarkable therapy, however, includes cytokine release syndrome and neurotoxicity shortly after administration as well as delayed infectious complications due to B\u2010cell aplasia. Future investigations are focused on the optimizing both safety and efficacy of CAR\u2010T cell therapy.<\/jats:p>","DOI":"10.1002\/hon.2568","type":"journal-article","created":{"date-parts":[[2018,11,14]],"date-time":"2018-11-14T15:04:12Z","timestamp":1542207852000},"page":"233-239","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The acceleration of CAR\u2010T therapy in non\u2010Hodgkin lymphoma"],"prefix":"10.1002","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8079-9443","authenticated-orcid":false,"given":"Pashna N.","family":"Munshi","sequence":"first","affiliation":[{"name":"Lombardi Comprehensive Cancer Center MedStar Georgetown University Hospital  Washington DC USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chaitra","family":"Ujjani","sequence":"additional","affiliation":[{"name":"Seattle Cancer Care Alliance University of Washington\/Fred Hutchinson Cancer Research Center Seattle  Seattle Washington USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,11,27]]},"reference":[{"doi-asserted-by":"publisher","key":"e_1_2_4_2_1","DOI":"10.1182\/blood-2017-03-769620"},{"doi-asserted-by":"publisher","key":"e_1_2_4_3_1","DOI":"10.1084\/jem.102.2.157"},{"doi-asserted-by":"publisher","key":"e_1_2_4_4_1","DOI":"10.1023\/A:1004654415985"},{"doi-asserted-by":"publisher","key":"e_1_2_4_5_1","DOI":"10.1038\/nrc1167"},{"doi-asserted-by":"publisher","key":"e_1_2_4_6_1","DOI":"10.1182\/blood-2008-03-077974"},{"doi-asserted-by":"publisher","key":"e_1_2_4_7_1","DOI":"10.1126\/scitranslmed.3002842"},{"doi-asserted-by":"publisher","key":"e_1_2_4_8_1","DOI":"10.1126\/scitranslmed.aaa3643"},{"doi-asserted-by":"publisher","key":"e_1_2_4_9_1","DOI":"10.4049\/jimmunol.1500751"},{"issue":"8","key":"e_1_2_4_10_1","first-page":"539","article-title":"A spacer region between the single chain antibody and the CD3 zeta\u2010chain domain of chimeric T\u2010cell receptor components is required for efficient ligand binding and signaling activity","volume":"2","author":"Moritz D","year":"1995","journal-title":"Gene Ther"},{"doi-asserted-by":"publisher","key":"e_1_2_4_11_1","DOI":"10.1158\/2326-6066.CIR-14-0127"},{"doi-asserted-by":"publisher","key":"e_1_2_4_12_1","DOI":"10.1016\/j.ymthe.2005.04.016"},{"doi-asserted-by":"publisher","key":"e_1_2_4_13_1","DOI":"10.1016\/j.ccell.2015.09.004"},{"doi-asserted-by":"publisher","key":"e_1_2_4_14_1","DOI":"10.1158\/0008-5472.CAN-11-0103"},{"doi-asserted-by":"publisher","key":"e_1_2_4_15_1","DOI":"10.1182\/blood-2011-12-400044"},{"doi-asserted-by":"publisher","key":"e_1_2_4_16_1","DOI":"10.1038\/leu.2010.75"},{"doi-asserted-by":"publisher","key":"e_1_2_4_17_1","DOI":"10.1038\/mt.2015.4"},{"key":"e_1_2_4_18_1","first-page":"1","article-title":"Axicabtagene ciloleucel, a first\u2010in\u2010class CAR T cell therapy for aggressive NHL","volume":"23","author":"Roberts ZJ","year":"2017","journal-title":"Leuk Lymhoma"},{"doi-asserted-by":"publisher","key":"e_1_2_4_19_1","DOI":"10.1038\/mto.2016.15"},{"doi-asserted-by":"publisher","key":"e_1_2_4_20_1","DOI":"10.1016\/S1525-0016(16)33096-9"},{"issue":"1","key":"e_1_2_4_21_1","article-title":"Long\u2010term follow\u2010up ZUMA\u20101: a pivotal trial of axicabtagene ciloleucel (axi\u2010cel; KTE\u2010C19) in patients with refractory aggressive non\u2010Hodgkin lymphoma (NHL) [ASH Abstract 578]","volume":"130","author":"Locke FL","year":"2017","journal-title":"Blood"},{"doi-asserted-by":"publisher","key":"e_1_2_4_22_1","DOI":"10.1016\/j.ymthe.2016.10.020"},{"doi-asserted-by":"publisher","key":"e_1_2_4_23_1","DOI":"10.1056\/NEJMoa1707447"},{"issue":"1","key":"e_1_2_4_24_1","article-title":"Primary analysis of JULIET: a global, pivotal, phase 2 trial of CTL019 in adult patients with relapsed or refractory diffuse large B\u2010cell lymphoma [ASH abstract 577]","volume":"130","author":"Schuster SJ","year":"2017","journal-title":"Blood"},{"issue":"1","key":"e_1_2_4_25_1","article-title":"An updated analysis of JULIET, a global pivotal phase 2 trial of tisagenlecleucel in adult patients with relapsed\/refractory (R\/R) diffuse large B cell lymphoma","volume":"2","author":"Borchmann P","year":"2018","journal-title":"HemaSphere"},{"issue":"2","key":"e_1_2_4_26_1","article-title":"High CR rates in relapsed\/refractory (R\/R) aggressive B\u2010NHL treated with the CD19\u2010directed CAR T cell product JCAR017 (TRANSCEND NHL 001) [ICML Abstract 128]","volume":"35","author":"Abramson JS","year":"2017","journal-title":"Hematol Oncol"},{"doi-asserted-by":"publisher","key":"e_1_2_4_27_1","DOI":"10.1200\/JCO.2018.36.5_suppl.120"},{"doi-asserted-by":"publisher","key":"e_1_2_4_28_1","DOI":"10.1016\/j.bbmt.2016.09.002"},{"doi-asserted-by":"publisher","key":"e_1_2_4_29_1","DOI":"10.1200\/JCO.2005.00.240"},{"doi-asserted-by":"publisher","key":"e_1_2_4_30_1","DOI":"10.1200\/JCO.2016.71.3024"},{"doi-asserted-by":"publisher","key":"e_1_2_4_31_1","DOI":"10.1200\/JCO.2014.56.2025"},{"doi-asserted-by":"publisher","key":"e_1_2_4_32_1","DOI":"10.1182\/blood.V126.23.184.184"},{"key":"e_1_2_4_33_1","first-page":"S791","article-title":"Updated phase 1 results from Zuma\u20101: a phase 1\u20102 multicenter study evaluating the safety and efficacy of KTE\u2010C19 (anti CD19 CAR T cells) in refractory aggressive B\u2010cell non Hodgkin lymphoma (NHL)","volume":"21","author":"Siddiqi T","year":"2016","journal-title":"Mol Ther"},{"doi-asserted-by":"publisher","key":"e_1_2_4_34_1","DOI":"10.1038\/nrclinonc.2018.20"},{"doi-asserted-by":"publisher","key":"e_1_2_4_35_1","DOI":"10.1038\/mto.2016.11"},{"doi-asserted-by":"publisher","key":"e_1_2_4_36_1","DOI":"10.1182\/blood-2014-05-552729"},{"doi-asserted-by":"publisher","key":"e_1_2_4_37_1","DOI":"10.1016\/S0140-6736(14)61403-3"},{"doi-asserted-by":"publisher","key":"e_1_2_4_38_1","DOI":"10.1038\/nrclinonc.2017.148"},{"doi-asserted-by":"publisher","key":"e_1_2_4_39_1","DOI":"10.1186\/s13045-018-0627-z"},{"doi-asserted-by":"publisher","key":"e_1_2_4_40_1","DOI":"10.1158\/2159-8290.CD-16-0040"},{"doi-asserted-by":"publisher","key":"e_1_2_4_41_1","DOI":"10.1016\/j.bbamcr.2011.01.034"},{"doi-asserted-by":"publisher","key":"e_1_2_4_42_1","DOI":"10.1126\/scitranslmed.3005930"},{"doi-asserted-by":"publisher","key":"e_1_2_4_43_1","DOI":"10.1182\/blood-2011-10-384388"},{"doi-asserted-by":"publisher","key":"e_1_2_4_44_1","DOI":"10.1038\/nrclinonc.2018.19"},{"doi-asserted-by":"publisher","key":"e_1_2_4_45_1","DOI":"10.1016\/j.jcyt.2017.06.001"},{"doi-asserted-by":"publisher","key":"e_1_2_4_46_1","DOI":"10.1038\/leu.2015.247"},{"doi-asserted-by":"publisher","key":"e_1_2_4_47_1","DOI":"10.1186\/s13045-018-0653-x"},{"doi-asserted-by":"publisher","key":"e_1_2_4_48_1","DOI":"10.1158\/2159-8290.CD-17-0698"},{"doi-asserted-by":"publisher","key":"e_1_2_4_49_1","DOI":"10.1182\/blood-2017-07-793760"},{"doi-asserted-by":"publisher","key":"e_1_2_4_50_1","DOI":"10.1126\/science.1088547"},{"doi-asserted-by":"publisher","key":"e_1_2_4_51_1","DOI":"10.1038\/nrc1122"},{"doi-asserted-by":"publisher","key":"e_1_2_4_52_1","DOI":"10.1172\/JCI35798"},{"doi-asserted-by":"publisher","key":"e_1_2_4_53_1","DOI":"10.1056\/NEJMoa1708566"},{"doi-asserted-by":"publisher","key":"e_1_2_4_54_1","DOI":"10.1126\/science.276.5319.1719"},{"doi-asserted-by":"publisher","key":"e_1_2_4_55_1","DOI":"10.1016\/S1470-2045(09)70074-9"},{"doi-asserted-by":"publisher","key":"e_1_2_4_56_1","DOI":"10.1182\/blood-2004-11-4564"},{"doi-asserted-by":"publisher","key":"e_1_2_4_57_1","DOI":"10.1126\/science.1231143"},{"doi-asserted-by":"publisher","key":"e_1_2_4_58_1","DOI":"10.1007\/s13238-017-0411-9"},{"doi-asserted-by":"publisher","key":"e_1_2_4_59_1","DOI":"10.1016\/j.ymthe.2017.06.014"},{"doi-asserted-by":"publisher","key":"e_1_2_4_60_1","DOI":"10.1158\/2326-6066.CIR-15-0276"},{"unstructured":"US National Library of Science.ClinicalTrials.gov[online]2016.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00881920","key":"e_1_2_4_61_1"},{"unstructured":"US National Library of Science.ClinicalTrials.gov[online]2016.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01316146","key":"e_1_2_4_62_1"},{"unstructured":"US National Library of Science.ClinicalTrials.gov[online]2015.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02315612","key":"e_1_2_4_63_1"},{"doi-asserted-by":"publisher","key":"e_1_2_4_64_1","DOI":"10.1038\/mt.2010.313"},{"doi-asserted-by":"publisher","key":"e_1_2_4_65_1","DOI":"10.1111\/imr.12125"},{"doi-asserted-by":"publisher","key":"e_1_2_4_66_1","DOI":"10.1038\/mto.2016.14"},{"doi-asserted-by":"publisher","key":"e_1_2_4_67_1","DOI":"10.1200\/JCO.2017.35.15_suppl.3025"},{"doi-asserted-by":"publisher","key":"e_1_2_4_68_1","DOI":"10.3390\/ijms19020340"},{"issue":"1","key":"e_1_2_4_69_1","article-title":"Phase 1 results from Zuma\u20106: axicabtagene ciloleucel (axi\u2010cel: KTE\u2010c19) in combination with atezolizumab for the treatment of patients with refractory diffuse large B cell lymphoma (DLBCL) [ASH abstract 2826]","volume":"130","author":"Locke FL","year":"2017","journal-title":"Blood"},{"doi-asserted-by":"publisher","key":"e_1_2_4_70_1","DOI":"10.1038\/mt.2015.104"},{"doi-asserted-by":"publisher","key":"e_1_2_4_71_1","DOI":"10.1126\/scitranslmed.aaj2013"},{"unstructured":"QuasimW CiocarlieO AdamsS et al.UCART19 an allogeneic anti\u2010CD19 CAR T\u2010cell product in high risk pediatric patients with CD19+ relapsed\/refractory B\u2010cell ALL: preliminary results of PALL study. EHA Learning Center. Qasim W. Jun 15 2018; 214671","key":"e_1_2_4_72_1"},{"doi-asserted-by":"crossref","unstructured":"JainN GrahamC KonoplevaM et al.UCART19 an allogeneic Anti\u2010CD19 CAR T\u2010cell product in high risk adult patients with CD19+ relapsed\/refractory B\u2010cell acute lymphoblastic leukemia: preliminary results of phase I CALM study. EHA Learning Center. Benjamin R.2018; 214674. Abstract PF 178.","key":"e_1_2_4_73_1","DOI":"10.1182\/blood.V130.Suppl_1.887.887"}],"container-title":["Hematological Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhon.2568","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.2568","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hon.2568","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.2568","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T00:09:13Z","timestamp":1694045353000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hon.2568"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,27]]},"references-count":72,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["10.1002\/hon.2568"],"URL":"https:\/\/doi.org\/10.1002\/hon.2568","archive":["Portico"],"relation":{},"ISSN":["0278-0232","1099-1069"],"issn-type":[{"type":"print","value":"0278-0232"},{"type":"electronic","value":"1099-1069"}],"subject":[],"published":{"date-parts":[[2018,11,27]]},"assertion":[{"value":"2018-11-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-11-07","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-11-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}